|
LAAO Trial Review, Medtronic Acquires Contego, and PFS Cuts Petition By Viktor Zarev
November 19, 2026
|
|
|
|
|
Together with
|
|
|
|
I’ve seen a lot of debate over LAAO since the CHAMPION-AF trial tried, and kinda failed, to settle the debate once and for all. I’ve also seen some of the most brilliant people in the world turn into keyboard warriors over whether or not it’s okay to support or scrutinize LAAO devices.
Whatever the truth may be, today’s top story reminded me that every patient is an individual.
Thank you for reading,
Viktor Zarev, Senior Editor
|
|
|
Surgeries & Interventions
|
|
|
|
|
|
Left atrial appendage occlusion (LAAO) has become one of cardiology’s most contentious therapies. Now, a new JACC evidence review argues that the answer comes from looking at patients as individuals rather than study populations.
- Trials like OPTION, CLOSURE-AF and CHAMPION-AF, provide evidence about LAAO outcomes, but each has raised new questions about ischemic risk and bleeding.
- Despite murky data, Boston Scientific’s Watchman series of LAAO devices has been implanted in 600k+ patients since its 2009 European launch and 2015 FDA approval.
To settle the score, a research team at Mass General Brigham appraised seven LAAO RCTs one at a time, but wisely didn’t pool their results because the trials differ too much in patients, devices, comparators, and endpoints.
- The seven trials spanned some of the earliest devices compared against warfarin to, DOAC-era comparisons, and newer phenotype-specific studies.
- By size, Boston Scientific’s CHAMPION-AF was the largest with WATCH-TAVR the smallest.
The MGB appraisal also mentions the recent ASAP-TOO study which randomized patients unsuitable for OAC to Watchman or a single antiplatelet/no therapy control but was stopped early due to low enrollment.
- ASAP-TOO was meant to be a test of the ideal LAAO candidate
- It yielded some encouraging results like lower ischemic stroke or systemic embolism rates (7.8% vs. 11.4%).
- But it likely wouldn’t have closed the evidence gap even if it continued.
But here’s the catch to all of this appraisal – most of the pivotal trials were designed to prove noninferiority, not superiority.
- When a study claims LAAO is “just-as-good-as” an oral blood thinner, it leaves physicians with a lot of clinical uncertainty.
Thus, the MGB team asks – what does this mean for clinical practice? At the end of the day, anticoagulation is still first-line for most patients while LAAO is reasonable when long-term OAC is unsafe or unsustainable.
- One hypothesis is that the best fit for LAAO is a patient with high stroke risk who also has high bleeding risk or repeat bleeds despite optimized therapy.
- But, that patient also shouldn’t be frail, and their anatomy should fit a device.
- And it’s worth noting that neither the CHA2DS2-VASc nor HAS-BLED risk calculators can pick out these patients from the crowd.
The Takeaway
Does LAAO work? Yes, but not for everyone, and it seems like the way forward for the occlusion side isn’t to totally replace oral anticoagulants. Rather, we need to define the exact patients who truly benefit from a permanent implant over a pill that can be discontinued at any time.
|
|
Meet with Optum at RSNA 2026
Whether you’re evaluating PACS replacement, cloud migration, AI readiness or enterprise imaging expansion, meet with Optum at RSNA to see the latest advancements and explore practical strategies for modernizing imaging while reducing complexity.
|
|
ALL‑RISE Trial Results Are In
The CathWorks FFRangio™ system met noninferiority to wire-based physiology for MACE at one year with statistically significant improvement in resource utilization and reduced procedure time. CathWorks FFRangio™ system is the new standard in coronary physiology. See the ALL-RISE data.
The information provided by the CathWorks FFRangio™ system is intended to be used by a qualified clinician in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional evaluation. Source: Fearon et al. NEJM 2026. doi: 10.1056/NEJMoa2600949
|
|
- Medtronic Scoops Up Contego: Medtronic is acquiring Contego Medical for ~$380M, turning a partnership that began with a 2020 investment and a 2025 exclusive U.S. distribution deal into full ownership. The prize at the center of the acquisition is Contego’s Neuroguard IEP Direct and Embolic Protection systems for carotid stenting, which picked up updated FDA approvals days before the announcement. Medtronic expects the deal to close by its fiscal Q3 and is openly gunning to become the carotid revascularization leader.
- Contego’s Embolic Protection PMA: Getting more specific about Contego Medical’s approvals, it earned FDA PMA approval for its Neuroguard IEP Direct System and 510(k) clearance for its Neuroguard IEP Embolic Protection System. The combo of technologies pairs flow reversal with an integrated filter and its approvals stemmed from the PERFORMANCE III pivotal study, in which Neuroguard posted a 0% 30-day stroke rate and a 0.69% major adverse event rate (ITT).
- Remedy Robotics’ Big Series B: Sticking with vascular dealmaking, Remedy Robotics raised $62M in Series B financing on the idea that robots can widen access to endovascular stroke and cardiac care. The San Francisco-based startup will use the fresh funds for clinical research, prototype deployment, and a pivotal trial across the University of California network for its AI-powered N1 System. Remedy’s founders claim their end-goal is full autonomy for these endovascular robots.
- Cangrelor Falls Short in Shock: A new study in The Lancet reminds us that drug efficacy can be largely situational. The double-blind trial pitted IV cangrelor against crushed ticagrelor in 605 acute MI patients with cardiogenic shock finding that cangrelor won the lab race and reached effective platelet inhibition by the end of PCI in 100% of tested patients vs. 22% with ticagrelor. However, in the real world, cangrelor’s 30-day death, MI, or ischemic stroke rate (38% vs. 41%) didn’t meet non-inferiority, and major bleeding was similar (6% vs. 5%).
- Acoramidis Gains Ground on Tafamidis: Results from BridgeBio’s mODIficATTR claims study suggest that patients starting acoramidis instead of tafamidis were less likely to need ramped-up diuretics. Among the study’s 1.1k patients, those on acoramidis faced a 23% lower risk of oral diuretic intensification (35% vs. 43% at 12 months). These results mirrored the ATTRibute-CM data from AHA that showed a 45% lower risk of first HF event vs. placebo, with benefit emerging within a month. This head-to-head data is observational, though, so confounding is quite possible.
- MYQORZO Takes on Beta-Blockers: Beta-blockers have anchored oHCM care for decades, but that’s changing with the FDA approval of Cytokinetics’ sNDA for MYQORZO. The new approval adds Phase 3 MAPLE-HCM data to MYQORZO’s (aficamten) label, making it the only cardiac myosin inhibitor with U.S. label data versus a beta-blocker. That’s because aficamten beat metoprolol as a monotherapy when it came to peak VO2 at 24 weeks and five of six secondary endpoints, though hypertension was more common (15% vs. 3%).
- Hello Heart’s HF Cost Guard: Hello Heart launched Hello Guard, a heart failure program that pairs a connected scale, BP monitor, and pill box with its AI assistant Nia and cardiologist review to catch decline before it becomes a hospitalization. The pitch to health plans is all about costs as first-year HF spending averages $45,893 per patient. Hello Heart’s core program was linked to ~$7k lower first-year spending and 47 fewer admissions per 100 HF participants, but that’s matched-cohort data, and Hello Guard itself has no outcomes yet.
- Cardiology Groups Take On PFS Cuts: Medicare physician pay has dropped ~33% since 2001 after adjusting for practice cost inflation. Now cardiology wants Congress to stop the compensation bleed. An AMA-led letter from 60+ groups, including ACC, HRS, SCAI, and STS, asks lawmakers to fix the 2027 PFS before Jan. 1 by extending the 2.5% payment update, passing the Provider Reimbursement Stability Act, delaying the modifier 25 cut a year, and capping MIPS penalties at 2%. That MIPS one hurts especially, since ~40% of solo clinicians were penalized under the rule this year.
- Veterans’ Heart Health Complexities: An AHA scientific statement in Circulation aims to explain why U.S. veterans’ cardiovascular health remains far from ideal. Veterans make up over 5% of the U.S. population, and more than half get care outside the VA’s ~9 million-person system. They skew older, rural, and less digitally connected, with higher rates of disability, PTSD, substance use disorder, and chronic pain that complicate adherence and lifestyle change. All of those features add layers of complexity to the heart risk veterans face.
- Sacubitril/Valsartan Curbs AFib After Ablation: Sacubitril/valsartan may have a role beyond heart failure. In the open-label SUPERIOR trial, 320 hypertensive patients undergoing first-time AF ablation at three Chinese centers were randomized to sacubitril/valsartan or valsartan starting the day after the procedure. At one year, atrial arrhythmia recurrence was 18.0% versus 28.3% (HR 0.58), with no difference in BP lowering, so the benefit isn’t just a BP effect. SUPERIOR’s open-label design and intermittent monitoring mean a blinded trial is still needed.
- What’s In A Name? Could how hard your last name is to pronounce impact your heart attack care? One BMJ study suggests so. Researchers examined 1,208 STEMI cases and classified the patients as having either phonetically common or uncommon surnames, finding that those with uncommon surnames experienced prolonged FMC-to-diagnosis time (+16.8 min) and FMC-to-balloon time (+17.5 min). Patients with uncommon names were also significantly more likely to exceed the 90 min FMC-to-balloon threshold (39.2% vs 48.4%) and the 120 min threshold (16.4% vs 23.5%).
|
|
ECG Analysis That Fits Your Device
Building a cardiac-monitoring product? ECG software should fit the application, whether it runs on a compact device or a server-based platform. Explore how Monebo works with developers to configure ECG analysis for different hardware, workflows, and integration needs.
|
|
Canon’s 30 Years of Caring
For over 30 years, Canon has helped advance pediatric interventional cardiology through innovation and a commitment to better care. Learn more about how and why modern pediatric cardiac angiography came to be from one of its founding members, Dr. John P. Cheatham.
|
|
Pulmonary Hypertension Detection With a Single Echo Clip
Pulmonary hypertension is often diagnosed late, when irreversible vascular remodelling has already occurred. That’s changing, however, with Us2.ai’s spatiotemporal transformer technology that can process apical four-chamber echo and accurately detects pulmonary hypertension far beyond the single-view echocardiographic benchmark.
|
|
- PIA Medical Processes It All: Need an analysis like calcium scoring, strain or even FFR? PIA Medical began as a Core Lab and can handle creative cardiac research and clinical trials along with the full breadth of clinical analyses available today.
- Merge Cardio 12.5 is Officially Available! From AI-generated echo measurements to upgraded UI and reports, Merge Cardio 12.5 brings a long list of new innovations to the table. Find out more about how Merge Cardio’s latest version streamlines workflows to make your cardiovascular service line more cost-effective and patient-centered.
- VASCADE MVP® XL Vascular Closure System: Sometimes EP procedures call for a venous vascular closure system that is simply bigger. Haemonetics’ VASCADE MVP XL closure system comes with 58% more collagen and a 9% larger disc compared to the VASCADE MVP system as well as an expanded indication for utilizing 10-14F inner diameter sheaths.
- How Automated MRI Software Transformed Radiology Regional: Radiology Regional recently integrated automated MRI scanning software into their imaging practice imaging. Hear from their team how automating CMR scans transformed their practice and enhanced patient care.
- How to Operationalize and Scale a New CV Service Line: Advances in AI, imaging, and coronary CT are creating new opportunities for cardiovascular care. Explore this Frost & Sullivan Executive Brief for the key things to consider when establishing a coronary plaque service line—from choosing your delivery model to integrating AI cardiovascular imaging workflows and capturing reimbursement value.
- State-of-the-Art Cardiac Monitoring at Scale: Cleared for 13 different heart rhythm interpretations, AccurKardia’s AccurECG 2.0 shortens the time from an arrhythmia incident to clinical intervention. Watch here to find out how AccurKardia and Specialized Medical are teaming up to bring the AccurECG 2.0 technology to clinicians across the U.S.
- From Fetal to Adult Cardiovascular Ultrasound: Continuity of care is critical when it comes to a patient’s cardiovascular health. That’s why cardiologists across America are picking Fujifilm’s Lisendo 880 cardiovascular ultrasound for its versatility and precise imaging starting at a patient’s fetal development to adulthood.
- HFSA Late-Breaker Findings: New research presented as a Late Breaker at HFSA demonstrated that patients receiving CCM® Therapy experienced significant long-term improvements in heart failure hospitalization rates and other key measures of cardiac health, including NT-proBNP, functional status, quality of life, and diuretic use… Read More.
|
|
|
|
|